← SynDRA
L-365260
SynDRA canonical compound SYN0000352 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | CCKAR | CCKBR | KCNQ1 |
|---|
| Mechanism of action | CCK receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- CCK receptor antagonist
- CCKBR MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- HTR2A
- HTR2B
- KCNH2
- DRD1
- ADGRF1
- NEIL2
- HTR1E
- HTR2C
- HTR3A
- HTR6
- HTR7
- MPG
- MUTYH
- OGG1
- HTR1B
- OPRD1
- OPRK1
- OPRM1
- S1PR1
- SIGMAR1
- SLC6A2
- SLC6A3
- SMUG1
- TDG
- TMEM97
- HTR1D
- HTR1A
- ADRA1A
- DRD3
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB2
- AGTR1
- APLNR
- C5AR1
- CHRM4
- CX3CR1
- DRD2
- DRD4
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- 2016-06-07: L 365260
- L-365,260
- L 365260
- 1-(1-Methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl)-3-(3-methylphenyl)urea
- CHEMBL289498
- L365260
- AC1L2XQK
- [3H]L365260
- [3H]L-365,260
- GTPL879
- GTPL3477
- SCHEMBL1650330
- KDFQABSFVYLGPM-UHFFFAOYSA-N
- BDBM50452555
- (R)-L 365260
- L000333
- 1-Methyl-3-[3-(3-methylphenyl)ureido]-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one
- RefChem:151747
- UNII-370JHF4586
- KDFQABSFVYLGPM-QFIPXVFZSA-N
- orb1704438
- SCHEMBL5931098
- SCHEMBL29403509
- SCHEMBL31616010
- SCHEMBL31616154
- BDBM81962
- CHEBI:79548
- MFCD00869756
- PDSP1_000921
- PDSP2_000907
- AKOS024457284
- EBC-521283
- NCGC00371056-01
- DA-74857
- MS-26737
- HY-106840
- CS-0026693
- S-L-365,260
- G12793
Look up L-365260 in the interactive SynDRA portal →